AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding
James Spargo | July 15, 2024 | News story | Research and Development | Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding
Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. The funds will be put towards bringing the first of Spotlight Medical’s prognostic tests to the clinic.
The AI-driven prognosis test will be used to help physicians select the most effective treatment for cancer patients, ensuring they are not over- or under-treated, by utilising years of treatment data. Tests such as these will become more important as precision medicine develops, as they can ensure care is tailored individually to patients.
Benjamin Belot from Kurma Partners said, “We were impressed by the quality of the team and by their unique technology, quite different from what we usually see in the field of precision oncology.”
Christian Lautner from Heal Capital added, “We are convinced the Spotlight Medical team is perfectly positioned to bring an AI-empowered precision oncology platform to clinical practice and thereby have a lasting impact on patients’ lives.”
“We are thrilled to have the support of Kurma Partners and Heal Capital as we take this critical step towards transforming cancer treatment,” said Sylvain Berlemont, CEO of Spotlight Medical. “This investment will accelerate our mission to harness the power of AI in analysing patient data, providing physicians with the insights they need to make more informed treatment decisions.”
James Spargo
Related Content
BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer
Bristol Myers Squibb (BMS) has announced that its Opdivo (nivolumab) has been accepted, in combination …
Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer
Astellas Pharma, a pharmaceutical company creating medicines to address unmet medical needs, has announced that …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
